Compare Humana Inc (HUM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Humana Inc trades at $427.33 (market cap $50.48B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Humana Inc is far larger — about 6.7× Spyre Therapeutics Inc. Common Stock's market cap, and Humana Inc pays a 0.84% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HUM | SYRE | |
|---|---|---|
Market Cap | $50.48B | $7.52B |
Volume | 1,889,709 | 1,441,031 |
Sector | Health | Health |
52-Week High | $433.50 | $108.92 |
52-Week Low | $163.67 | $22.18 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $57.83B | $6.52B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $427.59, down 1.36% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is robust, reaching $129.66 billion in 2025, though net income margins have compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and strong institutional buying interest, while the company prepares for Q3 earnings on November 6.
The stock offers upside to the $469.89 consensus target but faces risks from margin pressure and regulatory scrutiny. Earnings beats in recent quarters support momentum, yet profitability trends and Medicare Advantage plan changes require monitoring for sustained growth.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
